Clinical Trials

You can help find a cure for Alzheimer’s by participating in a clinical trial.

Share:

Everyone who has ever been sick and taken a pill, even an over-the-counter pill, has benefited from medical research and from people willing to volunteer to test that pill’s safety and efficacy. The process of developing new drugs and treatments is long, expensive, and difficult. Owing to difficulties enrolling participants, 80% of clinical trials finish late, thereby delaying the finding of a treatment or a cure. UsAgainstAlzheimer’s is committed to speeding the clinical trial process. Volunteers, both with and without Alzheimer’s, are urgently needed to participate in clinical trials and studies.

 

START HERE to know

Is clinical research right for you?

Take a free, 4-minute assessment to learn more about clinical research and decide whether participating in a research study is right for you.

TAKE THE ASSESSMENT

 

SEARCH HERE to find

Ready to look for clinical trials?

New treatments could reach the market in the next five years

Each year, our researchers network, Researchers     AgainstAlzheimer’s, publishes an analysis of Alzheimer’s drugs in late-stage clinical trials to provide a sense of when the latest treatments could reach the market. Here is their most recent analysis.

Read ReportResearchersAgainstAlzheimer’s Drugs in Development Pipeline Analysis.

Read Press Release: 27 Phase III and 8 Phase II Alzheimer’s Drugs on Track to Launch in Next 5 Years, ResearchersAgainstAlzheimer’s Reports.

Listen: Talks with Drew Holzapfel, Director of ResearchersAgainstAlzheimer’s, and Dr. David Morgan, founding member of ResearchersAgainstAlzheimer’s.

We are focused on increasing diversity in clinical trials

Two of our two networksLatinosAgainstAlzheimer’s and AfricanAmericansAgainstAlzheimer’sare increasing awareness and clinical trial participation among these communities that are typically underrepresented in research.

See: Forget Me Not—a play presented by AfricanAmericansAgainstAlzheimer’s.

Listen: Alzheimer’s Talks—a discussion of the motivations and barriers of participation among diverse communities.

This call was hosted by Jason Resendez, Executive Director of LatinosAgainstAlzheimer’s, and Dr. Goldie Byrd, Director of the Center for Outreach in Alzheimer’s Aging and Community Health at North Carolina A&T State University. They were joined by Daisy Duarte and Valerie Smith, both of whom have volunteered for clinical trials and are also caregivers for loved ones with Alzheimer’s or memory loss.

Watch: Five Ways to Improve Minority Participation in Clinical Trialsa panel including Jason Resendez, Executive Director of LatinosAgainstAlzheimer’s.

  • $1 trillion

    The societal and economic cost of dementia worldwide.

  • 2003

    The last time a novel Alzheimer’s therapy reached the market

  • $2.6 billion

    The estimated cost of developing a novel drug therapy

We are committed to speeding the clinical trial process

Global Alzheimer’s Platform (GAP)

Part of the UsAgainstAlzheimer’s enterprise, the GAP Foundation is joining together leading academic researchers, pharmaceutical companies, nonprofit organizations and foundations, and governments around the world to establish a standing global trial-ready platform to drive quality, efficiency, and innovation in Alzheimer’s clinical trials. GAP seeks to reduce the length of clinical trials by up to two years by building a network of certified high-performance clinical trial sites committed to standardizing processes and performance measurements.

Single Endpoint for New Drug Approvals for Alzheimer’s Disease

Read Report: Single Endpoint for New Drug Approvals for Alzheimer’s Disease.

Read Press Release: Alzheimer’s Experts Call for Changes in FDA Drug Approval Standards to Stimulate Research and Development.

Listen: Alzheimer’s Talks with Dr. Howard Fillit, Founding Executive Director and Chief Science Officer at the Alzheimer’s Drug Discovery Foundation and a Founding Member of ResearchersAgainstAlzheimer’s.

Listen: Alzheimer’s Talks: Improving the Pace and Quality of Clinical Trials with Dr. Laurie Ryan, Chief of the Dementias of Aging Branch in the Division of Neuroscience at the National Institute on Aging.

Sign up to help drive new research and discoveries

A-LIST: An online community partnering with researchers for an Alzheimer’s cure. A-LIST members take surveys on what matters most to them to help researchers focus their work on the symptoms and issues that of most importance. The A-LIST supports AD-PACE, a patient-focused drug development initiative of UsAgainstAlzheimer’s.

Alzheimer's Disease Education and Referral Center (ADEAR): A tool to find Alzheimer’s disease clinical trials run by the National Institute on Aging at NIH.

Memory Strings Community: Connects people to Alzheimer’s research opportunities and helps more than 50 leading research institutions with their clinical trial recruiting efforts. Memory Strings is powered by the Global Alzheimer’s Platform Foundation, an initiative of UsAgainstAlzheimer’s.

Alzheimer's Prevention Registry (APR): Created by Banner Alzheimer’s Institute, this initiative seeks to provide information on the latest research news and support enrollment in studies across the country.

Listen: Alzheimer’s Talks with Dr. Eric Reiman, Executive Director of Banner, about APR and its prevention initiatives.

Healthy Brains: An interactive platform by the Cleveland Clinic to get a brain check-up, track progress and learn more about brain health. The registry will also is a recruitment tool for clinical trials.

Brain Health Registry: An online initiative to reduce the time and costs of clinical trials. Anyone age 18 or older may sign up to answer a short questionnaire and take online neuropsychological tests (brain games). Memory decline can happen over many years, so researchers hope to identify subtle declines that will help find appropriate participants for clinical trials.

Listen: Alzheimer’s Talks with Dr. Michael Weiner, Founder of the Brain Health Registry.